title: Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
abstract: A total of 4 men with benign prostatic hypertrophy who underwent medical castration therapy with a long-acting gonadotropin-releasing hormone agonist (leuprolide) for more than 6 months elected to add an estrogen transdermal patch (0.05 mg. to the skin biweekly) to the leuprolide regimen. The average prostatic size (transrectal ultrasound), serum prostate specific antigen (PSA) levels and symptoms of prostatism were dramatically decreased with leuprolide alone. The addition of estrogen for 6 months did not result in any change in prostate size, symptoms or serum PSA levels over that seen with leuprolide alone. The development of squamous metaplasia was noted in 1 man with leuprolide alone and in 1 man after the addition of estrogen. Immunohistochemical staining with anticytokeratin 903 antibodies reveals that squamous metaplasia appears to arise from prostatic basal cells. We postulate that the target cell for estrogen action in the prostate is the prostatic basal cell. In the absence of androgen the only direct effect of estrogens is the induction of squamous metaplasia.
authors.affiliation: Bronfman Department of Medicine, Mount Sinai Medical Center, New York, New York.
authors.forename: A C
authors.initials: AC
authors.lastname: Levine
authors.forename: A
authors.initials: A
authors.lastname: Kirschenbaum
authors.forename: M
authors.initials: M
authors.lastname: Droller
authors.forename: J L
authors.initials: JL
authors.lastname: Gabrilove
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide; D008297:Male; D011467:Prostate / Q000187:drug effects / Q000473:pathology*; D017430:Prostate-Specific Antigen; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000097:blood
chemical_list: D000951:Antigens, Neoplasm; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D017430:Prostate-Specific Antigen; D016729:Leuprolide